Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069342
Filing Date
2025-05-12
Accepted
2025-05-12 16:40:50
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q xene-20250331.htm   iXBRL 10-Q 2141161
2 EX-10.5 xene-ex10_5.htm EX-10.5 94594
3 EX-10.6 xene-ex10_6.htm EX-10.6 96045
4 EX-31.1 xene-ex31_1.htm EX-31.1 16834
5 EX-31.2 xene-ex31_2.htm EX-31.2 16822
6 EX-32.1 xene-ex32_1.htm EX-32.1 12082
7 EX-32.2 xene-ex32_2.htm EX-32.2 11506
  Complete submission text file 0000950170-25-069342.txt   7871013

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT xene-20250331.xsd EX-101.SCH 867552
68 EXTRACTED XBRL INSTANCE DOCUMENT xene-20250331_htm.xml XML 1349430
Mailing Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W
Business Address 200 - 3650 GILMORE WAY BURNABY A1 V5G 48W (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36687 | Film No.: 25935543
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)